These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 14724315)

  • 1. Combined estrogen-progestin oral contraceptives.
    Martinelli I; Battaglioli T; Mannucci PM
    N Engl J Med; 2004 Jan; 350(3):307-8; author reply 307-8. PubMed ID: 14724315
    [No Abstract]   [Full Text] [Related]  

  • 2. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives.
    Sidney S; Petitti DB; Soff GA; Cundiff DL; Tolan KK; Quesenberry CP
    Contraception; 2004 Jul; 70(1):3-10. PubMed ID: 15208046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives.
    Martinelli I; Sacchi E; Landi G; Taioli E; Duca F; Mannucci PM
    N Engl J Med; 1998 Jun; 338(25):1793-7. PubMed ID: 9632445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Oral contraception increases the chance of venous thrombosis in factor V Leiden mutation].
    Vandenbroucke JP; Briët E; Helmerhorst F; van der Meer FJ
    Ned Tijdschr Geneeskd; 1995 May; 139(21):1067-71. PubMed ID: 7783798
    [No Abstract]   [Full Text] [Related]  

  • 5. Life threatening pulmonary embolus in a factor V Leiden carrier on oral contraceptives: a case report.
    Saif MW; Volpe BT; Dailey M; Tsongalis GJ
    Conn Med; 1997 Jun; 61(6):333-7. PubMed ID: 9238827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.
    Kemmeren JM; Algra A; Meijers JC; Bouma BN; Grobbee DE
    Thromb Haemost; 2002 Feb; 87(2):199-205. PubMed ID: 11859850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of thrombosis related to hormone therapy.
    Sandset PM; Høibraaten E; Eilertsen AL; Dahm A
    Thromb Res; 2009; 123 Suppl 2():S70-3. PubMed ID: 19217481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?
    Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F
    Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma resistance to activated protein C: an important link between venous thromboembolism and combined oral contraceptives--a short review.
    Jespersen J
    Eur J Contracept Reprod Health Care; 1996; 1(1):3-11. PubMed ID: 9678132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ischemic colitis and acquired resistance to activated protein C in a woman using oral contraceptives.
    Mann DE; Kessel ER; Mullins DL; Lottenberg R
    Am J Gastroenterol; 1998 Oct; 93(10):1960-2. PubMed ID: 9772065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smoking in arterial and venous thrombosis: the missing link?
    Tosetto A
    Am J Hematol; 2008 Feb; 83(2):92. PubMed ID: 18058998
    [No Abstract]   [Full Text] [Related]  

  • 12. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.
    Emmerich J; Rosendaal FR; Cattaneo M; Margaglione M; De Stefano V; Cumming T; Arruda V; Hillarp A; Reny JL
    Thromb Haemost; 2001 Sep; 86(3):809-16. PubMed ID: 11583312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives.
    Aznar J; Vayá A; Estellés A; Mira Y; Seguí R; Villa P; Ferrando F; Falcó C; Corella D; España F
    Haematologica; 2000 Dec; 85(12):1271-6. PubMed ID: 11114134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Activated protein C resistance in factor V disease: how high is the risk of thrombosis?].
    Spannagl M; Schramm W
    Dtsch Med Wochenschr; 1998 Feb; 123(6):137-9. PubMed ID: 9505951
    [No Abstract]   [Full Text] [Related]  

  • 15. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk.
    Maxwell GL; Schildkraut JM; Calingaert B; Risinger JI; Dainty L; Marchbanks PA; Berchuck A; Barrett JC; Rodriguez GC
    Gynecol Oncol; 2006 Nov; 103(2):535-40. PubMed ID: 16740300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor V Leiden and third-generation oral contraceptives.
    Westhoff C
    Lancet; 1996 Feb; 347(8998):396-7. PubMed ID: 8598719
    [No Abstract]   [Full Text] [Related]  

  • 17. Thrombotic risk factors and oral contraception.
    Bokarewa MI; Falk G; Sten-Linder M; Egberg N; Blombäck M; Bremme K
    J Lab Clin Med; 1995 Sep; 126(3):294-8. PubMed ID: 7665978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prothrombin 20210A polymorphism and third generation oral contraceptives--a case report of coeliac axis thrombosis and splenic infarction.
    Gould J; Deam S; Dolan G
    Thromb Haemost; 1998 Jun; 79(6):1214-5. PubMed ID: 9657451
    [No Abstract]   [Full Text] [Related]  

  • 19. [What effects estrogen and progesterone have in the development of breast cancer, thrombosis and the function of the vocal cords].
    Pulkkinen M
    Duodecim; 1996; 112(4):282-3. PubMed ID: 10590642
    [No Abstract]   [Full Text] [Related]  

  • 20. Oral contraceptives and the risk of myocardial infarction.
    Tanis BC; van den Bosch MA; Kemmeren JM; Cats VM; Helmerhorst FM; Algra A; van der Graaf Y; Rosendaal FR
    N Engl J Med; 2001 Dec; 345(25):1787-93. PubMed ID: 11752354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.